Search results for "good"

showing 10 items of 5625 documents

Intra-Dialytic Electrostimulation of Leg Extensors May Improve Exercise Tolerance and Quality of Life in Hemodialyzed Patients

2011

Hemodialyzed (HD) patients with end-stage renal disease (ESRD) exhibit lower fitness as a consequence of chronic uremic changes that trigger various structural, metabolic, and functional abnormalities in skeletal muscles. The aim of this randomized study was to compare the effect of rehabilitation (RHB) training on a bicycle ergometer and electromyostimulation (EMS) of leg extensors in HD patients with ESRD. Thirty-two HD patients (18 men/14 women; mean age 61.1 ± 8.8 years) were randomized into three groups: (i) exercise training (ET; n = 11) on bicycle ergometer 2 × 20 min; (ii) EMS (n = 11) where stimulation (10 Hz) of leg extensors was applied for 60 min; and (iii) controls (CON; n = 10…

medicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyBiomedical EngineeringMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologylaw.inventionBiomaterials03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifelawInternal medicinemedicineProspective cohort studyWalking testbusiness.industryGeneral Medicinemedicine.diseaseUremiaMuscle atrophy3. Good healthCardiologyPhysical therapyBicycle ergometerHemodialysismedicine.symptombusinessArtificial Organs
researchProduct

What influence patients'choice for peritoneal dialysis? a qualitative study

2018

L’objectif de cette étude était d’identifier les facteurs qui influencent le choix de la dialyse péritonéale (DP) chez les patients insuffisants rénaux, dans un centre de dialyse en France offrant un dispositif d’éducation thérapeutique du patient (ETP) aux patients en pré-dialyse. Pour ce faire, nous avons mené trente six entretiens semi-directifs avec des patients, des médecins de l’équipe d’ETP et un cadre de santé. Nous avons également observé dix séances d’ETP afin d’explorer la nature des interactions entre les patients, leurs accompagnants et l’équipe soignante. Nos résultats révèlent que les facteurs qui poussent les patients à choisir la DP sont l’influence des proches, les préfére…

medicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyDialysis patientsPeritoneal dialysis03 medical and health sciences0302 clinical medicineéducation thérapeutiquedialyse à domicileTherapeutic patient educationmedicineIn patient030212 general & internal medicineElectrical and Electronic EngineeringIntensive care medicineInternal medicineDialysisdialyse péritonéale[SHS.SOCIO]Humanities and Social Sciences/Sociologybusiness.industryrelation thérapeutiquemedicine.diseaseRC31-1245Atomic and Molecular Physics and Optics3. Good healthDialysis methodbusinesschoix thérapeutiquePatient educationKidney disease
researchProduct

Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Societ…

2005

Patients undergoing allogeneic stem cell transplantation are at high risk for infection with a variety of pathogens during different phases of the procedure. Bacteria and fungi predominate the first phase until engraftment. During the second phase, from engraftment to about day 100, major infectious problems are caused by fungi and cytomegalovirus. Both pathogens remain important under continued immunosuppression, however, in the late post-transplantation period infections with encapsulated bacteria may become a problem. In this review the Infectious Diseases Working Party of the DGHO gives recommendations for prophylaxis of infections under allogeneic stem cell transplantation with drugs a…

medicine.medical_specialtymedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationNeutropenia03 medical and health sciences0302 clinical medicineAnti-Infective AgentsmedicineHumansTransplantation HomologousInfection controlAntibiotic prophylaxisIntensive care medicineBone Marrow TransplantationInfection Controlbusiness.industryImmunosuppressionHematologyAntibiotic ProphylaxisAntimicrobialmedicine.disease3. Good healthTransplantationOncology030220 oncology & carcinogenesisImmunologyPreventive Medicinebusiness030215 immunologyAnnals of Oncology
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct

MERIT Study – “Multicenter Evaluation of Patient- and Lesion-Specific Prognostic Factors for RadioImmunoTherapy with 90yttrium-Labeled Anti-CD20 in F…

2009

Abstract Abstract 4792 Background / Aim Although prognostic factors (PF) for conventional lymphoma therapy are well known and used in clinical practice and medical research, the PF for radioimmunotherapy (RIT) have not been fully defined until now. The aim of this prospective multicenter trial is to identify patient- and lesion-specific PF for a standard RIT using 90Yttrium-labeled anti-CD20-antibodies in relapsed or refractory follicular lymphoma (FL) by means of clinical and image data including FDG-PET and CT. To prove the feasibility of the multicenter web-based data collection and to assess the imaging data we performed an analysis on retrospective data. Material and methods This retro…

medicine.medical_specialtymedicine.medical_treatmentImmunologyStandardized uptake valueBiochemistryLesion03 medical and health sciences0302 clinical medicineMulticenter trialmedicineMedical imagingProspective cohort study030304 developmental biology0303 health sciencesbusiness.industryCell BiologyHematologymedicine.disease3. Good healthLymphomaRadioimmunotherapyRadiologyRefractory Follicular Lymphomamedicine.symptombusiness030215 immunologyBlood
researchProduct

Anesthetics and Cerebral Protection in Patients Undergoing Carotid Endarterectomy

2015

EREBRAL ISCHEMIA/HYPOXIA may occur in a vari-ety of perioperative circumstances. The main pathophy-siologic aspects involved in cerebral ischemia/reperfusion arecaused by adenosine triphosphate (ATP) consumption, theexcitotoxic actions of glutamate, changes in ionic homeostasis,and formation of free radicals (Fig 1). Outcomes from suchevents range from subclinical neurocognitive deficits to cata-strophic neurologic morbidity or death.

medicine.medical_specialtymedicine.medical_treatmentIschemiaCarotid endarterectomyAnesthesia GeneralNeuroprotectionSevofluraneBrain Ischemia03 medical and health sciences0302 clinical medicine030202 anesthesiologyInternal medicinemedicineAnimalsHumansIschemic PreconditioningSubclinical infectionEndarterectomy Carotidbusiness.industryGlutamate receptorPerioperativeHypoxia (medical)medicine.disease3. Good healthNeuroprotective AgentsAnesthesiology and Pain MedicineAnesthesiaAnesthetics InhalationCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgerymedicine.drugJournal of Cardiothoracic and Vascular Anesthesia
researchProduct

The diagnosis of and treatment recommendations for anxiety disorders.

2014

Anxiety disorders (panic disorder/agoraphobia, generalized anxiety disorder, social phobia, and specific phobias) are the most common mental illnesses. For example, the 12-month prevalence of panic disorder/agoraphobia is 6%.This guideline is based on controlled trials of psychotherapy and pharmacotherapy, retrieved by a systematic search for original articles that were published up to 1 July 2013. Experts from 20 specialty societies and other organizations evaluated the evidence for each treatment option from all available randomized clinical trials and from a synthesis of the recommendations of already existing international and German guidelines.403 randomized controlled trials were eval…

medicine.medical_specialtymedicine.medical_treatmentMEDLINElaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawRisk FactorsmedicineHumansIntensive care medicinePsychiatryPsychodynamic psychotherapyPsychotropic Drugsbusiness.industryGeneral MedicineGuidelineClinical Practice GuidelineAnxiety Disorders030227 psychiatry3. Good healthCognitive behavioral therapyPsychotherapyNeurologyPractice Guidelines as TopicAnxietymedicine.symptomReuptake inhibitorbusiness030217 neurology & neurosurgeryDeutsches Arzteblatt international
researchProduct

The EHA research roadmap

2021

International audience; In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research(1) aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1-2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published…

medicine.medical_specialtymedicine.medical_treatmentPlatelet disorderClinical scienceHematopoietic stem cell transplantation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinemedicineDiseases of the blood and blood-forming organsIntensive care medicine030304 developmental biology0303 health sciencesHematologybusiness.industryTransfusion medicineHematologyHemostatic Disorders3. Good healthBlood DisorderEuropean policy[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologiePerspective[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieRC633-647.5businessHemaSphere
researchProduct

Thrombolytic therapy for submassive pulmonary embolism.

2012

Approximately 10% of all patients with acute pulmonary embolism (PE) die within the first three months after diagnosis. However, PE is not universally life-threatening, but covers a wide spectrum of clinical severity and death risk. Thrombolytic treatment is indicated patients with acute massive PE who are at high risk for early death, i.e. those patients who present with arterial hypotension and shock. On the other hand, low molecular-weight heparin or fondaparinux is adequate treatment for most normotensive patients with PE. Recombinant tissue plasminogen activator, given as 100 mg infusion over 2 h, is the treatment of choice for patients with PE, although older regimens using urokinase …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseVentricular Dysfunction RightClinical Biochemistry030204 cardiovascular system & hematologyFondaparinuxlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawPolysaccharidesRisk FactorsInternal medicinemedicineHumansStreptokinaseThrombolytic Therapy030212 general & internal medicineIntensive care medicineUrokinaseClinical Trials as Topicbusiness.industryHeparinThrombolysisHeparin Low-Molecular-Weightmedicine.diseaseUrokinase-Type Plasminogen ActivatorTroponin3. Good healthPulmonary embolismRadiographyOncologyFondaparinuxTissue Plasminogen ActivatorAcute DiseaseCardiologybusinessPulmonary EmbolismBiomarkersmedicine.drugCohort studyBest practiceresearch. Clinical haematology
researchProduct

Can transcranial direct current stimulation (tDCS) improve impulsivity in healthy and psychiatric adult populations? A systematic review.

2020

Impulsivity is a multidimensional phenomenon that remains hard to define. It compounds the core pathological construct of many neuropsychiatric illnesses, and despite its close relation to suicide risk, it currently has no specific treatment. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique whose application results in cognitive function improvement, both in healthy and psychiatric populations. Following PRISMA recommendations, a systematic review of the literature concerning tDCS's effects on impulsive behaviour was performed using the PubMed database. The research was based on the combination of the keyword 'tDCS' with 'impulsivity', 'response i…

medicine.medical_specialtymedicine.medical_treatment[SDV]Life Sciences [q-bio]CravingImpulsivityTranscranial Direct Current Stimulation03 medical and health sciences0302 clinical medicineRisk-TakingmedicineHumansPsychiatryBiological PsychiatryResponse inhibitionCravingPharmacologyTranscranial direct-current stimulationCognition3. Good health030227 psychiatryDorsolateral prefrontal cortex[SDV] Life Sciences [q-bio]Disruptive Impulse Control and Conduct DisordersInhibition Psychologicalmedicine.anatomical_structureDelay DiscountingBrain stimulationImpulsive Behaviormedicine.symptomConstruct (philosophy)PsychologyProgress in neuro-psychopharmacologybiological psychiatry
researchProduct